Abstract
The importance of omega-3 poly-unsaturated fatty acids (PUFAs) to improve several medical conditions is well recognized. More recently, these agents, because of their role of stabilization of neuronal membranes, have been considered in the treatment of various psychiatric disorders. The aim of this review is to provide a complete account of the empirical evidences of efficacy and safety for eicosapentaenoic acid (EPA), docosaexaenoic acid (DHA) and other less used PUFAs in the management of mental illness. There is little evidence to support the use of omega-3 fatty acids in the treatment of schizophrenia and of conditions characterized by high level of impulsivity and aggression. The most convincing findings are in favour of the use of PUFAs for mood disorders, especially unipolar and bipolar depression (but not mania). Concerning ADHD, trials are characterized by considerable heterogeneity in methods and omega-3 fatty acids supplementation exhibits modest benefits compared with traditional pharmacotherapy. On the basis of available data, omega-3 PUFAs cannot be unequivocally recommended as a monotherapy or adjunctive-therapy in any mental disorder. Although these compounds represent a novel and attractive modality of treatment, also considering good tolerability and safety, further studies are required to confirm omega-3 fatty acids supplementation as an effective intervention in psychiatric disorders.
Keywords: Omega-3 fatty acids, eicosapentaenoic acid, docosaexaenoic acid, schizophrenia, mood disorders, anxiety disorders, attention deficit hyperactivity disorder, impulsivity, efficacy, adverse effects, Psychiatric Disorders, leukotriens, poly-unsatured fatty acids, synaptic membrane, neuronal cell membrane
Current Psychopharmacology
Title:Omega-3 Fatty Acids Supplementation in Psychiatric Disorders: A Systematic Review
Volume: 1
Author(s): Silvio Bellino, Paola Bozzatello, Elena Brignolo, Chiara Brunetti and Filippo Bogetto
Affiliation:
Keywords: Omega-3 fatty acids, eicosapentaenoic acid, docosaexaenoic acid, schizophrenia, mood disorders, anxiety disorders, attention deficit hyperactivity disorder, impulsivity, efficacy, adverse effects, Psychiatric Disorders, leukotriens, poly-unsatured fatty acids, synaptic membrane, neuronal cell membrane
Abstract: The importance of omega-3 poly-unsaturated fatty acids (PUFAs) to improve several medical conditions is well recognized. More recently, these agents, because of their role of stabilization of neuronal membranes, have been considered in the treatment of various psychiatric disorders. The aim of this review is to provide a complete account of the empirical evidences of efficacy and safety for eicosapentaenoic acid (EPA), docosaexaenoic acid (DHA) and other less used PUFAs in the management of mental illness. There is little evidence to support the use of omega-3 fatty acids in the treatment of schizophrenia and of conditions characterized by high level of impulsivity and aggression. The most convincing findings are in favour of the use of PUFAs for mood disorders, especially unipolar and bipolar depression (but not mania). Concerning ADHD, trials are characterized by considerable heterogeneity in methods and omega-3 fatty acids supplementation exhibits modest benefits compared with traditional pharmacotherapy. On the basis of available data, omega-3 PUFAs cannot be unequivocally recommended as a monotherapy or adjunctive-therapy in any mental disorder. Although these compounds represent a novel and attractive modality of treatment, also considering good tolerability and safety, further studies are required to confirm omega-3 fatty acids supplementation as an effective intervention in psychiatric disorders.
Export Options
About this article
Cite this article as:
Bellino Silvio, Bozzatello Paola, Brignolo Elena, Brunetti Chiara and Bogetto Filippo, Omega-3 Fatty Acids Supplementation in Psychiatric Disorders: A Systematic Review, Current Psychopharmacology 2012; 1 (4) . https://dx.doi.org/10.2174/2211556011201040353
DOI https://dx.doi.org/10.2174/2211556011201040353 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
Neuromodulation for the treatment of psychiatric disorders
Neuromodulation techniques, including transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), magnetic seizure therapy (MST), electroconvulsive therapy (ECT), theta burst stimulation (TBS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS), have been widely employed in the therapeutic management of prevalent psychiatric conditions such ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genomic Variations Affecting Biological Effects of Statins
Current Drug Metabolism Is BMI Associated with COVID-19 Severity? A Retrospective ObservationalStudy
Current Medicinal Chemistry Hyperhomocysteinemia and Endothelial Dysfunction
Current Hypertension Reviews Targeted Drug Delivery for Cardiovascular and Cerebrovascular Diseases
Current Drug Targets Targeting Leukotrienes for the Treatment of COPD?
Inflammation & Allergy - Drug Targets (Discontinued) Preface [Hot Topic: The Roller Coaster of Antioxidant Therapy (Guest Editor: Francesco Visioli)]
Current Medicinal Chemistry Vascular Dysfunction and Insulin Resistance in Aging
Current Vascular Pharmacology Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Coronary Artery Disease and End-Stage Renal Disease - A Clinical Perspective
Current Hypertension Reviews Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Elevated Urinary and Blood Vascular Cell Adhesion Molecule-1 as Potential Biomarkers for Active Systemic Lupus Erythematosus: A Meta-analysis
Current Pharmaceutical Design Determinants of the Resolution of Type 2 Diabetes After Bariatric Surgery
Vascular Disease Prevention (Discontinued) Hybrid Stress Testing by Adenosine Infusion and Exercise Myocardial Perfusion Imaging: A Critical Appraisal
Current Cardiology Reviews Matrix Metalloproteinases: A Potential Therapeutic Target in Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Salt: A Review of its Role in Food Science and Public Health
Current Nutrition & Food Science Exosome-like Nanoparticles: A New Type of Nanocarrier
Current Medicinal Chemistry Effects of Insulin on the Vasculature
Current Vascular Pharmacology Multicomponent Reactions for the Synthesis of Bioactive Compounds: A Review
Current Organic Synthesis